Data presented at TCT will show whether the 'dissapearing' stent is a breakthrough in PCI

September 28, 2015

NEW YORK, NY - SEPTEMBER 28, 2015 - Noteworthy data will be presented at Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium next month on several trials examining the use of cardiovascular stents (or "scaffolds") that are absorbed back into the body over time.

"It really is a thrilling new technology and development for the stent field," said Juan F. Granada, MD, Executive Director and Chief Innovation Officer of the CRF Skirball Center for Innovation and Co-Director of the TCT Conference. "Developed with materials that naturally resorb into the artery following implantation, bioresorbable stents give us an opportunity to treat the lesion and avoid the potential risks that exist by having the stent in the body for an extended period of time."

The first bare-metal stents were very effective, but presented a risk of restenosis, or recurrence of the blockage. Drug-eluting stents then reduced restenosis, but with an increased risk of stent thrombosis occurring over time, a complication thought to be related to the potential interference of the permanently implanted stent with normal vessel healing. Over the last 15 years, significant refinements in stent design have drastically reduced these complications and now drug-eluting stents are considered the standard of care for many patients currently undergoing percutaneous coronary interventions.

Data on several late-breaking clinical trials will be presented at TCT:

"There is a great deal of excitement regarding the results of these studies that are being presented at TCT. It has been a while since there was this much enthusiasm in the field of coronary intervention, and these stents have the potential to add significantly to our armamentarium for treating patients with coronary artery disease in a minimally invasive approach," said Ajay J. Kirtane, MD, SM, Co-Director of TCT. He is also Director of Cardiac Catheterization Laboratories and Chief Academic Officer of the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center.
About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with heart disease through high quality research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. For more than 25 years, TCT has featured major medical research breakthroughs and gathered leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit and

Cardiovascular Research Foundation

Related Stents Articles from Brightsurf:

3D printed stents that treat inflammation
POSTECH Professor Dong-Woo Cho's research team develops bioink-loaded esophageal stents for treating radiation esophagitis.

Study could be first step in providing personalized care to patients with ureteral stents
Published today in Cell Reports Medicine, researchers at Lawson Health Research Institute and Western University conducted a novel microbiome study to examine bacteria associated with ureteral stents.

Two paths better than one for treating patients with heart stents
Pairing a blood-thinning drug with aspirin daily for patients who have an angioplasty with a stent can contribute to better health outcomes, including lower risk of death, than aspirin alone, according to a recent study by cardiologists at the University of Alberta and Mazankowski Alberta Heart Institute.

Open heart surgery outperforms stents in patients with multivessel disease
Coronary artery bypass grafting (CABG) surgery may be the best treatment option for most patients with more than one blocked heart artery, according to research published today in The Annals of Thoracic Surgery, published by Elsevier.

For infants with heart disease, are shunts or stents better to maintain blood flow?
Infants with various forms of congenital heart disease require a stable source of blood flow to their lungs in order to survive until a more definitive operation can be performed.

3-D-printed polymer stents grow with pediatric patients and biodegrade over time
A new study demonstrates proof-of-concept for combining computational design and simulation tools with 3-D printing technology to produce self-expandable polymer stents that can grow with pediatric patients, are biodegradable, and require only a minimally-invasive procedure for implantation.

Cardiologist warns against dissolvable stents in NEJM
In a New England Journal of Medicine (NEJM) editorial published last week, Debabrata Mukherjee, M.D., provides expert commentary on bioresorbable stents, an alternative to the traditional stents used in patients with cardiac conditions.

A simple fix to avoid some unnecessary coronary stents
Physician researchers at Thomas Jefferson University suspect that some cases of coronary artery spasm go unrecognized and are incorrectly treated with stents.

For malignant biliary obstruction, plastic stents may be cost-effective alternative
Preoperative biliary drainage (PBD) with stent placement has been commonly used for patients with malignant biliary obstruction.

3-D printing customized vascular stents
Using high-resolution 3-D printing, Northwestern University researchers can create flexible, biodegradable stents on-demand that are customized for a patient's specific anatomy.

Read More: Stents News and Stents Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to